155 related articles for article (PubMed ID: 38683443)
1. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
2. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
[TBL] [Abstract][Full Text] [Related]
3. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
Grazziotin LR; Currie G; Twilt M; Ijzerman MJ; Kip MMA; Koffijberg H; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung RSM; Marshall DA
Pediatr Rheumatol Online J; 2022 Apr; 20(1):25. PubMed ID: 35410419
[TBL] [Abstract][Full Text] [Related]
4. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
[TBL] [Abstract][Full Text] [Related]
5. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate for juvenile idiopathic arthritis.
Tan J; Renton WD; Whittle SL; Takken T; Johnston RV; Tiller G; Munro J; Buchbinder R
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003129. PubMed ID: 38334147
[TBL] [Abstract][Full Text] [Related]
8. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
[TBL] [Abstract][Full Text] [Related]
9. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
Brik R; Gepstein V; Berkovitz D
Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
[TBL] [Abstract][Full Text] [Related]
11. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
[TBL] [Abstract][Full Text] [Related]
12. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
[TBL] [Abstract][Full Text] [Related]
13. Juvenile Idiopathic Arthritis.
Barut K; Adrovic A; Şahin S; Kasapçopur Ö
Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
16. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
17. What are the factors associated with the duration of remission of intra-articular corticosteroid injection in juvenile idiopathic arthritis?
Aydın F; Çakar N; Kurt T; Çelikel Acar B; Çelikel E; Özçakar ZB; Yalçınkaya F
Clin Rheumatol; 2022 Dec; 41(12):3791-3796. PubMed ID: 35953685
[TBL] [Abstract][Full Text] [Related]
18. Intraarticular infliximab therapy in patients with juvenile idiopathic arthritis: the role of musculoskeletal ultrasound and disease activity scores in monitoring therapy response.
Vidovic M; Lamot L; Lamot M; Harjacek M
Clin Exp Rheumatol; 2018; 36(4):676-682. PubMed ID: 29600948
[TBL] [Abstract][Full Text] [Related]
19. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
[TBL] [Abstract][Full Text] [Related]
20. Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.
Arnstad ED; Rypdal V; Peltoniemi S; Herlin T; Berntson L; Fasth A; Nielsen S; Glerup M; Ekelund M; Zak M; Aalto K; Nordal E; Romundstad PR; Rygg M;
Arthritis Care Res (Hoboken); 2019 Jul; 71(7):961-969. PubMed ID: 30055093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]